Nintedanib, the NEMO Trial, and What They Mean for Pleural Mesothelioma Patients

A recently published clinical study in Lung Cancer sheds light on why some experimental treatments do not always translate into better outcomes for mesothelioma patients. Malignant pleural mesothelioma is a rare and aggressive cancer most often linked to asbestos exposure, and despite advances in care, long‑term survival remains limited. For years, researchers have searched for ways to slow the disease after initial chemotherapy, particularly by targeting the biological processes that help tumors grow and spread.

This trial, called Nintedanib as Switch Maintenance Treatment in Malignant Pleural Mesothelioma (NEMO), focused on nintedanib, a drug designed to block signals that promote new blood vessel formation and tissue scarring, both of which play a role in mesothelioma progression. In theory, stopping these processes could help keep the cancer controlled after standard treatment. To test this idea, researchers enrolled patients whose disease had not worsened after completing first‑line chemotherapy. These patients were then randomly assigned to receive either nintedanib or a placebo as ongoing maintenance therapy, treatment given to delay progression.

The study was carefully designed to minimize bias, with neither patients nor doctors knowing which treatment was being given. However, the trial was stopped early after enrolling 37 patients. This was largely because results from a similar, larger study published during the same period showed no benefit from nintedanib, making it harder to justify continued enrollment. As a result, the researchers emphasize that the findings should be viewed as descriptive rather than definitive.

The investigators found that nintedanib did not help patients live longer without their disease worsening. In fact, the time before cancer progression was slightly shorter in patients receiving nintedanib than in those receiving placebo. Overall survival results also favored the placebo group, with patients in that group living longer on average. While this may seem surprising, the researchers caution that this difference is unlikely to mean the drug itself was harmful. Instead, it highlights how access to subsequent treatments can affect outcomes.

A key factor was what happened after disease progression. Many more patients in the placebo group went on to receive immunotherapy, which other studies have shown can improve survival in mesothelioma. Far fewer patients in the nintedanib group received these newer therapies. This imbalance likely explains much of the survival difference between the two groups and underscores how rapidly evolving treatment options can complicate the interpretation of clinical trials.

The takeaway from the NEMO trial is an important one for patients and families navigating mesothelioma treatment decisions. Not every promising laboratory or early‑stage therapy ultimately benefits patients in real‑world settings. This study suggests that using nintedanib alone as maintenance therapy after chemotherapy does not improve outcomes for people with pleural mesothelioma. At the same time, it reinforces the growing importance of immunotherapy and combination approaches in modern mesothelioma care. While this particular drug did not deliver the hoped‑for results, ongoing research continues to inform better treatment strategies for those harmed by asbestos‑related disease.

If you or someone you love has been diagnosed with malignant pleural mesothelioma after exposure to asbestos, you don’t have to navigate the medical and legal challenges alone. Brayton Purcell LLP has spent decades advocating for mesothelioma victims and their families, holding accountable the companies that caused this preventable disease. To learn more about your legal rights and options for pursuing compensation, contact Brayton Purcell LLP today for a free, no‑obligation consultation.